科研之友
微信
新浪微博
Facebook
分享链接
摘要
To eliminate systemic toxicity, including the hypotension associated with human tumor necrosis factor cy (TNF-(alpha), we constructed mutant proteins (muteins) by mean of genetic engineering. A novel mutein, F4614, containing mutations of (5)Thr --> Gly and (6)Pro --> Asp, which resulted in the introduction of cell-adhesive Arg-Gly-Asp and (29)Arg --> Val, had remarkably reduced hypotensive effects and lower lethality, We present evidence that the Arg --> Val mutation at position 29 is largely responsible for the reduced hypotensive effect. This effect of F3614 was thought to be closely correlated with its low inducibility of nitric oxide and prostaglandin E(2) in vivo. In addition, the therapeutically effective dose of F46P4 to MethA fibrosarcoma-transplanted mice was increased compared with that of TNF-alpha. Indicating a wide therapeutic index. These results indicated that F4614 has several advantages as a systemic therapeutic drug in the treatment of cancer.
- 出版日期1995-8
